Plasma Cytokine Responses Characterized in Melioidosis
By LabMedica International staff writers Posted on 04 Dec 2019 |
Image: Colonies of Burkholderia pseudomallei on Ashdown`s agar after four days` incubation (Photo courtesy of Gavin Koh)
Melioidosis, an infectious disease caused by the environmental saprophyte Burkholderia pseudomallei, is endemic across many areas of Southeast Asia, South Asia, Northern Australia and America. B. pseudomallei is a facultative intracellular bacterium, a characteristic that contributes to its pathogenesis and persistence in the host and that may modulate the cytokine response to infection.
Patients may present with a wide range of clinical manifestations including pneumonia, bacteremia, abscesses, and sepsis, frequently leading to multiorgan failure and eventually death. The immunological markers and pathways that identify patients at risk of death in melioidosis are not well understood. Several immune cells including macrophages, natural killer (NK) cells, NK T cells, and T cells respond to bacterial infection rapidly by generation of several potent cytokines.
Microbiologists and immunologists at the Mahidol University (Bangkok, Thailand) conducted a prospective longitudinal study in two hospitals in Northeast Thailand to enroll 161 melioidosis patients, 13 uninfected healthy controls, and 11 uninfected diabetic controls. Blood was obtained from all individuals at enrollment (day 0) and at days 5, 12, and 28 from surviving melioidosis patients. IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-23, and TNF-α were assayed in plasma. These were determined in human plasma samples using bead-based multiplex assays of Luminex technology (MILLIPLEX MAP kit: HSTCMAG-28K-12 plex, Millipore, Billerica, MA, USA). The association of each cytokine and its dynamics with 28-day mortality was determined.
The investigators reported that of melioidosis patients, 131/161 (81%) were bacteremic, and 68/161 (42%) died. On enrollment median levels of IFN-γ, IL-6, IL-8, IL-10, IL-23, and TNF-α were higher in melioidosis patients compared with uninfected healthy controls and all but IFN-γ were positively associated with 28-day mortality. IL-8 provided the best discrimination of mortality. Over time, non-survivors had increasing IL-6, IL-8, and IL-17A levels, in contrast to survivors. In joint modeling, temporal trajectories of IFN-γ, IL-6, IL-8, IL-10, and TNF-α predicted survival.
The authors concluded that in a severely ill cohort of melioidosis patients, specific pro- and anti-inflammatory and Th17 cytokines were associated with survival from melioidosis, at enrollment and over time. Persistent inflammation preceded death. These findings support further evaluation of these mediators as prognostic biomarkers and to guide targeted immunotherapeutic development for severe melioidosis. The study was published on November 7, 2019 in the journal Clinical Microbiology and Infection.
Related Links:
Mahidol University
Millipore
Patients may present with a wide range of clinical manifestations including pneumonia, bacteremia, abscesses, and sepsis, frequently leading to multiorgan failure and eventually death. The immunological markers and pathways that identify patients at risk of death in melioidosis are not well understood. Several immune cells including macrophages, natural killer (NK) cells, NK T cells, and T cells respond to bacterial infection rapidly by generation of several potent cytokines.
Microbiologists and immunologists at the Mahidol University (Bangkok, Thailand) conducted a prospective longitudinal study in two hospitals in Northeast Thailand to enroll 161 melioidosis patients, 13 uninfected healthy controls, and 11 uninfected diabetic controls. Blood was obtained from all individuals at enrollment (day 0) and at days 5, 12, and 28 from surviving melioidosis patients. IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-23, and TNF-α were assayed in plasma. These were determined in human plasma samples using bead-based multiplex assays of Luminex technology (MILLIPLEX MAP kit: HSTCMAG-28K-12 plex, Millipore, Billerica, MA, USA). The association of each cytokine and its dynamics with 28-day mortality was determined.
The investigators reported that of melioidosis patients, 131/161 (81%) were bacteremic, and 68/161 (42%) died. On enrollment median levels of IFN-γ, IL-6, IL-8, IL-10, IL-23, and TNF-α were higher in melioidosis patients compared with uninfected healthy controls and all but IFN-γ were positively associated with 28-day mortality. IL-8 provided the best discrimination of mortality. Over time, non-survivors had increasing IL-6, IL-8, and IL-17A levels, in contrast to survivors. In joint modeling, temporal trajectories of IFN-γ, IL-6, IL-8, IL-10, and TNF-α predicted survival.
The authors concluded that in a severely ill cohort of melioidosis patients, specific pro- and anti-inflammatory and Th17 cytokines were associated with survival from melioidosis, at enrollment and over time. Persistent inflammation preceded death. These findings support further evaluation of these mediators as prognostic biomarkers and to guide targeted immunotherapeutic development for severe melioidosis. The study was published on November 7, 2019 in the journal Clinical Microbiology and Infection.
Related Links:
Mahidol University
Millipore
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms